major depressive disorder

Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
CP Wire
SAGE Therapeutics
FDA
breakthrough status
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
SAGE Therapeutics
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Acceptance Growing for BrainsWay’s Depression Therapy
Acceptance Growing for BrainsWay’s Depression Therapy
Medical Devices and Diagnostics Industry
Brainsway
devices
Deep Transcranial Magnetic Stimulation
major depressive disorder
Flag link:
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
CP Wire
Assurex Health
GeneSight
major depressive disorder
Myriad Genetics
diagnostics
Flag link:
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
Assurex Health
GeneSight
major depressive disorder
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Alkermes
ALKS-5461
major depressive disorder
FDA
Flag link:
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Flag link:
Why FDA News About Alkermes ALKS 5461 Studies Is Not A Complete Surprise
Alkermes
ALKS 5461
major depressive disorder
Flag link:
FDA Rejects Alkermes NDA for Major Depressive Disorder Drug ALKS 5461
FDA Rejects Alkermes NDA for Major Depressive Disorder Drug ALKS 5461
CP Wire
Alkermes
FDA
depression
major depressive disorder
ALKS 5461
Flag link:
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Xconomy
SAGE Therapeutics
major depressive disorder
SAGE-217
Flag link:
Will third trial be the charm for Alkermes' depression drug?
Will third trial be the charm for Alkermes' depression drug?
Fierce Biotech
Alkermes
clinical trials
ALKS 5461
major depressive disorder
Flag link:
23andMe, Lundbeck unveil mega investigation of genetics' role in depression
23andMe, Lundbeck unveil mega investigation of genetics' role in depression
BioPharma Dive
23andMe
Lundbeck
genetics
bipolar disorder
major depressive disorder
Flag link:
Can Sage Therapeutics Press Even Further With Its Depression Trial?
Can Sage Therapeutics Press Even Further With Its Depression Trial?
Yahoo/24-7 Wall St
SAGE Therapeutics
major depressive disorder
SAGE-217
Flag link:
An Early Valuation Of Neuralstem's NSI-189 For MDD
An Early Valuation Of Neuralstem's NSI-189 For MDD
Seeking Alpha
Neuralstem
NSI-189
major depressive disorder
Flag link:
Alkermes announces advances with its late-stage CNS pipeline
Alkermes announces advances with its late-stage CNS pipeline
Yahoo/Fly on the Wall
Alkermes
aripiprazole lauroxil
schizophrenia
ALKS 5461
major depressive disorder
Flag link:
Lilly depression drug fails late-stage trial
Lilly depression drug fails late-stage trial
Yahoo/Reuters
Eli Lilly
edivoxetine
major depressive disorder
norepinephrine reuptake inhibitors
Flag link:
Alkermes depression drug gets fast track status
Alkermes depression drug gets fast track status
Bloomberg/Businessweek
Alkermes
fast track
ALKS 5461
antidepressants
major depressive disorder
Flag link:
Lundbeck, Takeda Win U.S. Approval for Depression Therapy
Lundbeck, Takeda Win U.S. Approval for Depression Therapy
Bloomberg
Lundbeck
Takeda
FDA
Brintellix
major depressive disorder
Flag link:
The Next Big Opportunity in Antidepressant Drugs
The Next Big Opportunity in Antidepressant Drugs
Motley Fool
antidepressants
Pfizer
Eli Lilly
Forest Labs
Cymbalta
Fetzima
Pristiq
major depressive disorder
Flag link:
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
Yahoo
FDA
Neuralstem
NSI-189
major depressive disorder
Flag link:

Pages